Composer · investment strategy
by Composer Technologies · via Composer
A daily biotech trend rider using 3x bull/bear ETFs. Trades LABU when short-term biotech trend is up, may flip to LABD on overbought wobble, and holds QQQ when no biotech uptrend. Uses very short moving averages and a short RSI. Very high risk.
Description from Composer
of the return and risk figures:as the source publishes them
What $10,000 would have become, from the strategy's own published history, against the S&P 500 over the same dates. The basis is labelled.
This strategy doesn’t publish a performance history we can chart.
Each rule is quoted word for word from the strategy's own documents.
No rules extracted from this strategy’s text yet.
1 positions as of 2026-10-11
: the platform's backtest holdings, not a client account.
Compares the stated rules with the holdings (or, where none are published, a mix estimated from returns), using tests fixed before any results were seen.
0.5% of weight in (IVV: 3.0%)
1 fund (SEC N-PORT, as of 2026-05-31) · : QQQ via QQQM
This strategy’s rules haven’t been extracted yet, so there’s no claim to compare with. The measurement is still shown. : 96% · 2026-10-11 ()
0.0% of weight in (SPY: 0%)
This strategy’s rules haven’t been extracted yet, so there’s no claim to compare with. The measurement is still shown. : 100% · 2026-10-11 ()
2 of 3 funds in its are : LABD, LABU
This strategy’s rules haven’t been extracted yet, so there’s no claim to compare with. The measurement is still shown. : 100%
Strategies that share its Thematic label, from other sources first, strongest risk-adjusted return first.
Interactive Advisors
How much of what we look for this strategy has, and why anything is missing. Fields that don't apply to it aren't counted.
4 missing
The text the rules are quoted from, with where it came from.
It trades the biotech sector using 3x ETFs: LABU (goes up when biotech rises) and LABD (goes up when biotech falls). If biotech’s short-term trend (2-day avg) isn’t above its 10-day avg, it parks in QQQ (big-tech). In uptrends it mostly holds LABU. If price gets very “hot” (RSI, a 0–100 heat gauge, is high), it uses tiny trend checks (2 vs 3-day averages) to flip briefly to LABD or back to LABU. Rebalances daily.
A daily biotech trend rider using 3x bull/bear ETFs. Trades LABU when short-term biotech trend is up, may flip to LABD on overbought wobble, and holds QQQ when no biotech uptrend. Uses very short moving averages and a short RSI. Very high risk.
Biotech-focused, 3x-levered strategy aiming for outsized gains: out-of-sample ~45% annualized vs S&P ~10–12%; alpha-driven with LABU/LABD hedges. Higher risk: max drawdown ~48% vs ~19% SPX. Suited for growth investors tolerating volatility.
Needs to be tuned. Badly.
Every value on file, each labelled with its calculation basis and as-of date.
| Backtest final value (from $10,000) | $5,495 | 2026-10-11 | |
| Backtest regulatory fees | $102 | 2026-10-11 | |
| Backtest slippage cost | $861 | 2026-10-11 |
| AI categories (Composer) | biotech, daily rebalance, leveraged etfs, long/short, momentum, moving averages, rsi, tactical allocation, trend-following | 2026-10-11 | |
| Asset classes / instruments | equities | 2026-10-11 |
| Logic complexity (node count) | 51 | 2026-10-11 | |
| Rebalance frequency | daily | 2026-10-11 |
| Concentration (Herfindahl index, out-of-sample, as Composer reports it) | 1 | 2026-10-11 | |
| Ticker universe (assets the logic can hold) | show[ "LABD", "LABU", "QQQ" ] | 2026-10-11 |
| Alpha vs SPY, out-of-sample (out-of-sample) | 0.32 | 2026-10-11 | |
| Beta vs SPY, out-of-sample (out-of-sample) | 1.34 | 2026-10-11 | |
| Correlation (R) vs SPY, out-of-sample (out-of-sample) | 0.37 | 2026-10-11 |
| Remixes (copies) | 9 | 2026-10-11 | |
| Watchers | 0 | 2026-10-11 |
| Community review status | ACTIVE | 2026-10-11 |
| Backtest length | 2,800 | 2026-10-11 | |
| Out-of-sample length | 495 | 2026-10-11 | |
| Return, backtest period (annualized) (backtest) | -5.24% | 2026-10-11 | |
| Return, backtest period (cumulative) (backtest) | -45.05% | 2026-10-11 | |
| Return, out-of-sample period (annualized) (out-of-sample) | 45.33% | 2026-10-11 | |
| Return, out-of-sample period (cumulative) (out-of-sample) | 108.73% | 2026-10-11 | |
| Return, trailing 1 day (out-of-sample) | 0.49% | 2026-10-11 | |
| Return, trailing 1 month (out-of-sample) | -5.76% | 2026-10-11 | |
| Return, trailing 1 week (out-of-sample) | 0.23% | 2026-10-11 | |
| Return, trailing 1 year (backtest) | 15.57% | 2026-10-11 | |
| Return, trailing 1 year (out-of-sample) | 15.59% | 2026-10-11 | |
| Return, trailing 2 weeks (out-of-sample) | 0.91% | 2026-10-11 | |
| Return, trailing 3 months (out-of-sample) | -7.63% | 2026-10-11 | |
| SPY annualized return over the backtest window (backtest) | 14.69% | 2026-10-11 |
| Calmar ratio, backtest period (backtest) | -0.05 | 2026-10-11 | |
| Calmar ratio, out-of-sample period (out-of-sample) | 0.95 | 2026-10-11 | |
| Maximum drawdown, backtest period (backtest) | -97.60% | 2026-10-11 | |
| Maximum drawdown, out-of-sample period (out-of-sample) | -47.93% | 2026-10-11 | |
| Sharpe ratio, backtest period (backtest) | 0.25 | 2026-10-11 | |
| Sharpe ratio, out-of-sample period (out-of-sample) | 0.92 | 2026-10-11 | |
| Sortino ratio, backtest period (backtest) | 0.36 | 2026-10-11 | |
| Sortino ratio, out-of-sample period (out-of-sample) | 1.39 | 2026-10-11 | |
| Standard deviation, backtest period (backtest) | 65.87% | 2026-10-11 | |
| Standard deviation, out-of-sample period (out-of-sample) | 59.99% | 2026-10-11 |
| Annualized turnover, backtest period (backtest) | 43.65 | 2026-10-11 | |
| Annualized turnover, out-of-sample period (out-of-sample) | 43.27 | 2026-10-11 | |
| Daily win rate, backtest period (backtest) | 53.07% | 2026-10-11 | |
| Daily win rate, out-of-sample period (out-of-sample) | 54.55% | 2026-10-11 |
Collective2
Composer Technologies · Composer
